Poland Integrated Medicines Management (PL-IMM) - Study Assessing the Provision of Complex Clinical Pharmacy Services to Hospitalized Patients

NCT ID: NCT07159932

Last Updated: 2025-09-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 610 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2027-12-30

Brief Summary

The aim of the study is to assess whether the involvement of a clinical pharmacist in patient care at every stage of hospitalization, from admission to discharge, will improve the quality of healthcare services provided in clinical and economic terms. As part of the research study, we will randomly assign you to two different groups.

Within one group, a pharmacist will be involved in the process of caring for you throughout your hospital stay. The pharmacist will participate in medical rounds, verify medications upon admission to the hospital, check current test results and medical orders regarding pharmacotherapy, verify medications upon discharge and provide advice on the use of medications. All activities will be carried out in consultation with other medical staff. The aim is to check whether such a model of patient care increases safety and leads to improved pharmacotherapy for patients, and also has a positive effect on patient satisfaction and compliance with therapeutic recommendations. Additionally, the opinion of the medical staff and the economic aspects of this solution will be assessed. Within the second group, you will receive standard care offered by the hospital. In the case of both groups, after the hospitalization is completed, the pharmacist will contact you after 1, 3, 6 months to verify your health condition - he or she will ask about any hospitalizations, complications, side effects, and additional visits to the doctor.

Detailed Description

Despite the benefits of clinical pharmacy services demonstrated in numerous publications and their implementation in many countries around the world, Poland has still not achieved nationwide implementation. There is also a lack of scientific data at the national level showing the benefits of including a pharmacist in the patient facing activities. Therefore, this RCT aimes to determine if pharmacist input at each stage of hospitalization, from admission to discharge, can result in an enhanced level of patient care when compared to standard care as measured by a number of clinical and economic outcomes. Given the aforementioned, the objective of this research is to:

1. Primary outcome: Determine the incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period.

2. Secondary outcome: Assess the length of stay (LoS) in hospital.

3. Additional outcomes:

• Evaluate the service by determining the frequency and type of interventions performed, their acceptance and influence on the quality of pharmacotherapy.
• Assess the perception of the service by patients.
• Assess the perception of the service by healthcare professionals.
• Estimate the potential financial benefits of the service.

Conditions

Acute Admitted Multimorbid Patients

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

Control group

Standard care during hospital stay, without pharmacist involved

Group Type: NO_INTERVENTION

No interventions assigned to this group

Pharmacist intervention - IMM

A pharmacist is included in the multidisciplinary treatment team during the hospital stay

Group Type: EXPERIMENTAL

multidisciplinary treatment

Intervention Type: BEHAVIORAL

The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information

Interventions

multidisciplinary treatment

The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• ≥18 years old and an acute admission to the hospital fulfilling at least one of the following criteria:

• taking ≥4 medicines
• taking high risk medicines listed in the medicines reconciliation standard of Polish Society of Clinical Pharmacy (….)
• medicine related admission to the hospital within last 12 months
• chronic kidney or liver disease
• after solid organ transplantation

Exclusion Criteria

• age below 18 years old
• pregnancy
• resident of long-term care facility
• unable to express informed consent to participate in the research
• expected survival less than 6 months

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wroclaw Medical University

OTHER

Sponsor Role: lead

Responsible Party

Kamila Urbańczyk

MPharm

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Regional Hospital in Wroclaw

Wroclaw, , Poland

Countries

Poland

Central Contacts

Kamila Urbańczyk, MPharm

Role: CONTACT

kamila.urbanczyk@umw.edu.pl

0048 71 32 70 427

Other Identifiers

KB 47O/2O23N

Identifier Type: -

Identifier Source: org_study_id